(MT Newswires) -- Dutch Philips Group (PHG) CEO Roy Jakobs discusses the consequences of the sleep apnea machine recall. The Dutch medical equipment manufacturer has not given a definitive figure for the cost of the recall, as the legal proceedings are not over, but claims that 99% of defective devices have been replaced. While the company has recorded three consecutive quarters of growth, it points to investments in artificial intelligence, estimated at over a billion euros a year.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
24.51 EUR | +1.70% | +1.53% | +20.22% |
06-19 | Philips: cancellation of almost 4.4 million shares | CF |
06-17 | Royal Philips Receives FDA 510(K) Clearance for Zenition 90 Motorized Mobile C-Arm | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.22% | 24.26B | |
+7.23% | 217B | |
+11.31% | 191B | |
+28.94% | 154B | |
+32.00% | 112B | |
+0.11% | 62.75B | |
+16.09% | 53.34B | |
+0.94% | 48.88B | |
-2.97% | 39.36B | |
+1.23% | 35.73B |
- Stock Market
- Equities
- PHIA Stock
- News Philips NV
- Product recalls, renewed growth, investment in AI. Roy Jakobs, Philips CEO